Abdel G Babiker
Dados Biográficos
| ID | 10714664 |
|---|---|
| NOME | Abdel G Babiker |
| PRENOMES | Abdel G |
| SOBRENOME | Babiker |
| ASSINATURA | BABIKER A G |
| AFILIAÇÕES | Medical Research Council |
| ORCID | 0000-0003-4711-3021 |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2008 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2020 |
| ÍNDICE H | 0 |
Remdesivir for the Treatment of Covid-19 — Final Report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (2…
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
BACKGROUND: In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial. METHODS: HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral …
Sem obras proeminentes nesta página.
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
BACKGROUND: In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial. METHODS: HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral …
Remdesivir for the Treatment of Covid-19 — Final Report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (2…
Medicine (2 obras) · Virology (2 obras) · 2019-20 coronavirus outbreak (1 obras) · Antibody (1 obras) · ANTIRETROVIRAL AGENTS (1 obras) · Antiretroviral therapy (1 obras) · Antiretroviral treatment (1 obras) · Coronavirus disease 2019 (COVID-19) (1 obras) · COVID-19 Clinical Research Studies (1 obras) · HIV-related health complications and treatments (1 obras)